Didier Scherrer is the founder of Abivax. Abivax has raised $204M in total funding. Latest round: IPO. Backed by Truffle Capital. Based in Paris, France.
Didier Scherrer is associated with Abivax, a clinical-stage biotechnology company founded in 2013 and headquartered in Paris, France. Abivax focuses on developing therapeutics that modulate the immune system for chronic inflammatory diseases, with operations in France and the United States.
Full founder directory · Investor directory · Company funding database · Fundraising library